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Twenty years of research and advances in 
pathophysiology have not yet translated into effective 
therapeutic tools for improving survival after an acute 
kidney injury (AKI) episode. AKI is a disease process 
characterised by rapidly decreasing renal excretory 
function, with accumulation of nitrogen metabolism and 
other waste products. AKI is a major public health concern 
with a rapidly increasing prevalence and unacceptably 
high mortality rate, claiming 1.7 million lives each year 
[1].
AKI is characterized by renal tubular damage, 
for which a plausible key mediator, amenable to 
pharmacological manipulation, has not been identified yet. 
Due to their high-energy demand, tubular cells are rich in 
mitochondria, and alterations in these organelles have been 
recognized as a hallmark in the initiation and progression 
of the disease [2]. Increased production of reactive oxygen 
species (ROS) and decreased antioxidant defences, make 
mitochondria particularly susceptible to injury [2]. 
These are highly mobile organelles that exist in dynamic 
networks whose function relies on complex molecular 
machinery, finely tuned and balanced between fission―
accompanied by mitochondrial membrane depolarization 
and oxidative damage―and fusion, more commonly 
leading to energy production. Mitochondrial fission is 
catalyzed by Dynamin Related Protein 1 (Drp1), which 
is recruited from the cytosol to the outer mitochondrial 
membrane by Mitochondria fission factor (Mff) to 
form spirals to sever both membranes of the organelle. 
Conversely, mitochondria join through the process of 
fusion, which is mediated by the coordinated activities of 
Mitofusins (Mfn) and Optic atrophy 1 (Opa1) in the outer 
and inner mitochondrial membrane, respectively. Fission 
and fusion may also serve as an important quality control 
mechanism for preserving the functional integrity of the 
mitochondrial network. Fusion helps to ease physiological 
stress levels by mixing the contents of partially damaged 
mitochondria as a form of complementation, while fission 
is needed to remove mitochondria from the network 
when the organelles become damaged and membrane 
potential depolarization occurs across the inner membrane. 
Depolarized mitochondria are substrates for the 
translocation of several proteins, such as PTEN-induced 
Putative Kinase 1 (PINK1), which tags the organelle for 
elimination through the mitophagic machinery. Ample 
evidence indicates that, in experimental models of 
AKI, mitochondrial fission predominates and organelle 
impairment precedes renal dysfunction [3].
Mitochondrial vitality appears to be maintained 
by Sirtuin 3 (SIRT3), which belongs to an evolutionarily 
conserved family of seven NAD+-dependent deacetylases, 
three of which (SIRT3-5) are mainly localized in the 
mitochondrion [4]. In previous studies we demonstrated 
that elevated renal SIRT3 expression reduces ROS and 
ameliorates mitochondria dynamics that translate into 
the longevity phenotype in mice deficient for angiotensin 
II type 1 receptor [5]. Whether renal SIRT3 could be a 
master regulator of injury and repair in AKI represented a 
logical extension of these studies.
Cisplatin was used in mice to induce AKI that, 
by affecting proximal tubular cells, leads to increased 
generation of ROS and changes in mitochondrial 
dynamics [6]. These abnormalities were associated 
with an 80% reduction in the renal expression of SIRT3 
mRNA and protein. In an attempt to pharmacologically 
manipulate the system, AICAR, an activator of the SIRT3 
upstream signal AMPK, or the antioxidant agent acetyl-
L-carnitine (ALCAR), were used. Both compounds 
improved renal function and ameliorated tubular injury in 
cisplatin-induced AKI mice. The renoprotective effect was 
accompanied by the upregulation of PGC-1α, a crucial 
mitochondrial biogenesis regulator able to promote SIRT3 
gene expression, and NAMPT, the rate-limiting enzyme in 
the biosynthesis of NAD+, ultimately leading to restoration 
of SIRT3 expression/activity. At the ultrastructural level, 
AICAR treatment tipped mitochondrial dynamics towards 
fusion, as it preserved mitochondrial fragmentation 
induced by the chemotherapic and reduced expression of 
the mitochondrial fission mediator Drp1 in the organelles 
of AKI mice.
In vitro, in tubular cells SIRT3 overexpression 
promoted mitochondrial fusion by limiting Drp1 
recruitment through the downregulation of Mff and by 
upregulating Opa1. Moreover, the overexpression of 
SIRT3 promoted mitochondrial integrity by counteracting 
the cisplatin-dependent mitochondrial membrane 
depolarization and translocation of PINK1 on the organelle 
membrane.
The biological and clinical relevance of SIRT3 in 
AKI was further documented in SIRT3-/- mice. In these 
animals, cisplatin induced earlier and remarkably more 
severe renal dysfunction and, unlike their WT littermates, 
all SIRT3-deficient mice died within 7 days. SIRT3-
deficient animals were fully resistant to the therapeutic 
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effects of both AICAR and ALCAR, which, conversely, 
were consistently beneficial to SIRT3-competent mice.
Taken together, our results indicate that SIRT3 is 
a crucial regulator of mitochondrial functional integrity 
and a non-redundant player in tubular injury and repair 
in AKI. Given the high prevalence of mitochondrial 
dysfunction in many chronic diseases, such as metabolic 
syndrome, premature ageing and cancer, along with the 
profound impact SIRT3 has on mitochondrial function 
and metabolism, the obvious translational consequence 
of these in vivo and in vitro studies will be to look for 
potential SIRT3-specific activating compounds, which 
the current pharmacopeia is remarkably lacking. Recent 
work has provided evidence that honokiol is capable of 
blocking cardiac hypertrophy by increasing SIRT3 activity 
[7], paving the way for disclosing novel SIRT3 activators. 
Now is the time for academia and industry to jointly tackle 
this challenge, offering hope to patients who still die of 
conditions that lack effective treatment.
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